Dr. Robinson is a physician scientist and radiation oncologist at Yale Cancer Center who specializes in the treatment of hematologic and CNS malignancies, with expertise in CNS hematologic malignancies and the use of radiation to improve the outcomes of patients with hematologic malignancies undergoing CAR T-cell therapy. Dr. Robinson helped pioneered the use of radiation therapy to improve the outcomes of patients undergoing CAR T-cell therapy, having published the first series demonstrating the safety of bridging radiation therapy for patients with DLBCL undergoing CAR T-cell therapy, as well as a seminal patterns of failure study in DLBCL patients treated with CAR T, which showed that over a third of treatment failures in DLBCL treated with CAR T are local-only, suggesting a rationale for aggressive bridging radiation therapy in patients with relatively localized or high risk disease. Dr. Robinson currently treats heme, CNS, and palliative patients at Yale Cancer Center within the Waterford, CT campus. In addition to his clinical research and practice, Dr. Robinson has a translational research program focused on aberrant mRNA splicing in hematologic malignancies and its role in mediating resistance to immune and cellular therapeutics. His lab conducts both bioinformatic and bench-based investigations focused on identifying, validating, and exploiting aberrant mRNA splicing in cancer.